INTRODUCTION: Bladder cancer (BCa) is one of the most prevalent malignancies worldwide, mostly due to its high recurrence rates. In consequence, the necessity of repeated screening for reappearance demonstrates the urgent need for novel biomarkers as alternatives to invasive standard procedures. METHODS: Proteomic technologies have emerged as powerful platforms for unbiased biomarker discovery and revolutionized the classical "target-driven" analysis of single marker candidates. Although proteome profiling is still far from demonstrating its full potential in clinical diagnosis, first studies clearly denote its significant potential. CONCLUSIONS: This review provides a discussion of the challenges related to clinical proteomics using mass spectrometry, emphasizing bladder cancer biomarker discovery. An outline of the technological prerequisites for reliable proteome profiling, data mining and interpretation, as well as, reflections on future trends in the field are provided.
INTRODUCTION:Bladder cancer (BCa) is one of the most prevalent malignancies worldwide, mostly due to its high recurrence rates. In consequence, the necessity of repeated screening for reappearance demonstrates the urgent need for novel biomarkers as alternatives to invasive standard procedures. METHODS: Proteomic technologies have emerged as powerful platforms for unbiased biomarker discovery and revolutionized the classical "target-driven" analysis of single marker candidates. Although proteome profiling is still far from demonstrating its full potential in clinical diagnosis, first studies clearly denote its significant potential. CONCLUSIONS: This review provides a discussion of the challenges related to clinical proteomics using mass spectrometry, emphasizing bladder cancer biomarker discovery. An outline of the technological prerequisites for reliable proteome profiling, data mining and interpretation, as well as, reflections on future trends in the field are provided.
Authors: Michael J Chalmers; Colin Logan Mackay; Christopher L Hendrickson; Stefan Wittke; Michael Walden; Harald Mischak; Danilo Fliser; Ingo Just; Alan G Marshall Journal: Anal Chem Date: 2005-11-15 Impact factor: 6.986
Authors: Dan Theodorescu; Stefan Wittke; Mark M Ross; Michael Walden; Mark Conaway; Ingo Just; Harald Mischak; Henry F Frierson Journal: Lancet Oncol Date: 2006-03 Impact factor: 41.316
Authors: Stephane Decramer; Stefan Wittke; Harald Mischak; Petra Zürbig; Michael Walden; François Bouissou; Jean-Loup Bascands; Joost P Schanstra Journal: Nat Med Date: 2006-03-19 Impact factor: 53.440